Loop Energy Records Over 75,000 Kilometers of Operation for Fuel Cell Municipal Bus Fleet in Nanjing, China
28.6.2021 15:00:00 EEST | Business Wire | Press release
Ahead of the company’s upcoming Investor Day, Loop Energy (TSX: LPEN), a developer and manufacturer of hydrogen fuel cell-based solutions, reports that the pilot transit bus fleet of Skywell New Energy Vehicles Group (Skywell) in Nanjing, China has now been fully operational for 45 days and has already accumulated 75,000 kilometers of in-service operations. Loop’s company management will share additional details about the fleet deployment and other business achievements for the Company during its Investor Day on Tuesday, June 29 at 10:00 a.m. PDT (1:00 p.m. EDT).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210628005227/en/
Loop Energy records over 75,000 kilometers of operation for fuel cell municipal bus fleet of Skywell New Energy Vehicles Group in Nanjing, China (Photo: Business Wire)
Loop Energy announced in April the fulfillment of a ten-unit order of the company’s proprietary eFlow® fuel cell modules from Beijing IN-Power for integration by Skywell. This marked the second phase milestone of a memorandum of understanding between the Lishui Economic Development Zone of Nanjing and Beijing IN-Power—Loop Energy’s China-based joint venture partner supplying the fuel cell engines.
“As we progress toward large-scale commercial deployment of hydrogen fuel cell vehicles in China, these impressive operational results demonstrate Skywell’s expertise, Loop’s product maturity, and the market’s accelerating adoption of hydrogen fuel cell technology,” said Ben Nyland, President and Chief Executive Officer of Loop Energy. “We are very pleased to see the strong results of our eFlow technology on the road, which continues to validate Loop’s unique value proposition of greater fuel efficiency, higher power, and extended range.”
“This pilot fleet deployment has gone exceptionally well and is setting the stage for continued success between Loop Energy and IN-Power as we continue to collaborate with Skywell to advance the fuel cell market in China,” said John Zhang, Founder and President of IN-Power.
“The Loop fuel cell systems are performing very well, and we are impressed with the quality of the product,” said Ms. Zou Ran (Joanna), Director of External Affairs & Brand of Skywell New Energy Vehicles Group. “The support of the IN-Power and Loop teams has been critical in achieving the rapid deployment of this pilot fleet and represents a major step towards reaching the objective of implementing similar fuel cell solutions across a wide range of our specialty and commercial vehicles.”
“We are extremely pleased with the successful operation of these zero-emission hydrogen electric buses,” said Mr. Cuichangong, Deputy Secretary of Party Work Committee of the Lishui Economic Development Zone. “This is another meaningful step in establishing the Lishui Economic Development Zone of Nanjing as a fuel cell and hydrogen centre of excellence in China and reaffirms our commitment to providing safe, reliable, energy-efficient transportation throughout the district.”
To learn more about the Skywell fleet deployment and performance, register to attend Loop Energy’s Investor Day video conference call at investors.loopenergy.com.
About Beijing IN-Power Electric Co., Ltd.
Founded in 2004, Beijing IN-Power is a high-tech Sino-foreign joint venture enterprise, headquartered in the High-tech Industrial Park, Zhongguancun, of Beijing. Through IN-Power’s two R&D Centers, and four wholly-owned subsidiaries and twenty-five offices all over China, the company is engaged in the development, manufacturing and integration of new energy and power electronics technology, equipment and engineering services. For more information, please visit http://en.in-power.net/.
About Skywell New Energy Vehicles Corp.
Skywell New Energy Vehicles Corp., formed in 2011 following the acquisition of Nanjing Jinlong Bus Manufacturing Co., is a leading developer and global supplier of electric vehicles. With headquarters located in the Lishui Airport Economic Development Zone in Nanjing, China, with production factories located in Wuhan, Shenzhen and Xianyang, Skywell manufactures and markets an extensive range of sustainable vehicles from light-duty automobiles, to medium and heavy-duty buses, commercial and specialty fleet trucks. The company also operates buses in the Lishui district of China. www.skywellcorp.com
About Loop Energy Inc.
Loop Energy is a leading designer and manufacturer of fuel cell systems targeted for the electrification of commercial vehicles, including, light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop’s products feature the Company’s proprietary eFlow™ technology in the fuel cell stack’s bipolar plates. eFlow™ was designed to enable commercial customers to achieve performance maximization and cost minimization. Loop works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop is driving towards a zero-emissions future, visit www.loopenergy.com.
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflect management’s current expectations regarding future events. Forward‐looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the ability of the Company to execute on its strategy and the factors discussed under “Risk Factors” in the final long-form prospectus of the Company dated February 18, 2021. Loop disclaims any obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005227/en/
Contact information
Loop Energy Media Contact: Ashley Eisner | Tel: +1.212.697.2600 | aeisner@gscommunications.com
Loop Energy Business Contact: George Rubin | Tel: +1.604.828.8185 | grubin@loopenergy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom